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Introduction: Use of autologous fat grafting (AFG) for breast reconstructive surgery is gaining acceptance,
but concerns regarding its efficacy and safety remain. We present a protocol for a systematic review that
aims to update the findings since our previous systematic review on a number of outcomes of AFG.
Methods: The systematic review has been registered a priori (UIN: reviewregistry308). All study designs,
including randomised controlled trials, cohort studies, case-controlled studies and case reports/series,
reporting original data, on women undergoing AFG for breast reconstruction following mastectomy or
breast conserving surgery, will be included. Six categorical outcomes will be assessed: oncological; clin-
ical; aesthetic/functional; patient-reported; process; and radiological.
The search strategy will be devised to investigate ‘fat grafting and breast reconstruction’. Electronic data-
bases will be searched, 01 April 2014 to 21 August 2017: PubMed, MEDLINE, EMBASE, SCOPUS, CINAHL,
PsychINFO, SciELO, The Cochrane Library, including the Cochrane Central Register of Controlled Trials
(CENTRAL), Database of Abstracts of Reviews of Effect (DARE), the Cochrane Methodology Register,
Health Technology Assessment Database, the NHS Economic Evaluation Databases and Cochrane
Groups, ClinicalTrials.gov, Current Controlled Trials Database, the World Health Organisation (WHO)
International Clinical Trials Registry Platform, UpToDate.com, NHS Evidence and the York Centre for
Reviews and Dissemination. Grey literature will be searched. Two trained, independent teams will screen
all titles and abstracts, and relevant full texts, for eligibility. Data will be extracted under standardised
extraction fields into a preformatted database.
Ethics and dissemination: The systematic review will be published in a peer-reviewed journal and pre-
sented at national and international meetings within fields of plastic, reconstructive and aesthetic sur-
gery, and surgical oncology. The work will be disseminated electronically and in print. Brief reports of
the review and findings will be disseminated to interested parties through email and direct communica-
tion. The review aims to guide healthcare practice and policy.
 2017 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction Autologous fat grafting (AFG) is a technique gaining popularity forBreast cancer is themost commoncancer inUK females,with over
50,000 new diagnoses each year in the UK [1]. The vast majority of
women diagnosed with breast cancer subsequently undergo surgery
with curative intent, eithermastectomy or breast conserving surgery
(BCS). Increasingly there is a trend towards BCS over mastectomy.
Surgery is often combined with radiotherapy or chemotherapy or
hormonal treatments in efforts to minimise likelihood of recurrence.both reconstructive and/or cosmetic indications. It involves harvest-
ing the patient’s own adipose tissue, from distant sites, and implant-
ing this tissue to the breast. There are several advantages to this
approach: the fat harvested is often in ample supply; the patient’s
own tissue is used; harvestingprocedures generally result inminimal
donor site morbidity or cosmetic disturbance; foreign body or com-
plicated flap procedures are avoided; procedures can be performed
as a day case; AFG can rejuvenate breast skin which antagonises the
effects of ageing and radiotherapy [2–4].
There are several disadvantages to consider with AFG [5–9].
Obtaining consistently good cosmetic and reconstructive results,
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Fig. 1. Number of articles published per year and indexed by SCOPUS under the
search term ‘‘fat grafting” AND ‘‘breast reconstruction”.
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loose and poorly vascularised space after BSC or mastectomy,
which puts it at risk of necrosis. Necrotic fat can instigate an
inflammatory reaction resulting in fibrosis, cyst formation, calcifi-
cation or local infection [10–13]. In 1987 the American Society of
Plastic and Reconstructive Surgeons (ASPRS) Ad Hoc Committee
on New Procedures therefore prohibited use of AFG to the female
breast [14]. Since then, there has been effort to develop techniques
to improve graft take and fat maintenance [4,14]. ‘Structural fat
grafting’ [10] where small aliquots of fat are transplanted through
multiple tunnels in a multi-layered and multidirectional way can
maximise adipocyte contact with host tissue and hence survival
and incorporation [11], and has been shown to be efficacious
[15]. The scarring and calcifications that can result from AFG might
mask detection of breast cancer on mammography. In one sample
as many as 16.7% of patients showed had microcalcification clus-
ters after AFG [16]. The ASPS, however, have stated there appears
to be no interference with breast cancer detection [13]. There are
additional concerns are that adipocytes transplanted into areas of
previous malignant change may directly stimulate the formation
of cancer [5]. Adipocyte tissue is increasingly recognised as an
endocrine organ, rich in mesenchymal stem cells (MSCs) [4]. Adi-
pocyte derived stem cells (ADSCs) have potential to differentiate
into cells including chondrocytes, osteocytes, myoblasts, and
secrete angiogenic factors [17]. Promotion of angiogenesis in a
tumour bed post mastectomy or BSC is of substantial oncological
concern. Adipocyte tissue has an integral role in breast cancer pro-
gression and in metastasis [6]. In animal studies engrafted MSCs
were less able to regulate growth patterns which could predispose
to cancer [7,8]. Due to the significant potential harmful effects of
AFG, in 2009 the American Society of Plastic Surgeons (ASPS) sta-
ted fat grafting was not strongly recommended by the Fat Grafting
Task force due to limited scientific data on safety and efficacy [13].
The potential advantages of AFG has stimulated significant
interest. It is essential to verify whether potential benefits of AFG
outweigh the potential risk. In 2014 we conducted a systematic
review [18] analysing the outcomes along the six dimensions of
oncological, clinical, aesthetic/functional, patient-reported, process
and radiological. The results of this review revealed significant
heterogeneity on studies reporting on AFG outcomes in terms of
techniques, patient population, indications and definitions, which
precluded a meta-analysis of results. Importantly findings indi-
cated no evidence that AFG promoted cancer recurrence or primary
cancer, overall complications were low and most patients and clin-
icians were satisfied with the results. However, most studies
included were of poor quality. Since 2014 there has been growing
interest and use of AFG techniques for breast reconstruction. A
basic search of the SCOPUS database for ‘‘fat grafting” and ‘‘breast
reconstruction” (Fig. 1). Since the start of January 2017 to the start
of August 2017, the SCOPUS search revealed that 54 articles had
since been published in this area. As the use of AFG in breast recon-
structive surgery is a rapidly developing area, an up-to-date sys-
tematic review and meta-analysis is needed.2. Objectives
The primary objective is to perform an up-to-date comprehen-
sive systematic review of AFG for breast reconstruction to deter-
mine the safety efficacy and radiological outcomes.2.1. Primary objectives
The primary objective is to determine outcomes of AFG for
breast reconstruction in women following mastectomy or BCS
along 6 dimensions:(1) Oncological.
(2) Clinical.
(3) Aesthetic/functional.
(4) Patient-reported.
(5) Process.
(6) Radiological.
2.2. Secondary objectives
The secondary objectives include
(1) Determine optimal methods of AFG including fat harvesting,
preparation and injection.
(2) Determine the indications of AFG.
(3) Refine the patient selection for AFG.
3. Method
This systematic review will be conducted in line with recom-
mendations specified in the Cochrane Handbook for Intervention
Reviews V.5.1.0 and is AMSTAR compliant [19] and reported in line
with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [20]. This protocol has been
developed a priori, and the systematic review has been registered
a prior on the Research Registry (UIN: reviewregistry308, www.
researchregistry.com. The methodology will closely follow that
used in the systematic review and meta-analysis in 2015 for max-
imum comparability [18].
4. Criteria
The following inclusion and exclusion criteria will be used to
minimise heterogeneity with previous reviews and address
research questions
5. Types of studies included
All original research studies, levels 1–5 of the Oxford Centre for
Evidence-Based Medicine [21] (randomised controlled trials
(RCTs), cohort studies, case-controlled, case series, case reports)
reporting on one or more of the outcomes of interest, will be
included. Unpublished data and reports will also be considered if
the methodology and data are accessible. Duplicate articles, cost-
effectiveness studies, studies not reporting on primary data
(review articles, editorials, discussions, commentaries, letters)
and studies not reporting on the indication for AFG, will be
excluded.
Table 1
An example of a preliminary MEDLINE conducted on 2nd August 2017.
Search
number
Search Studies
generated
1 Mammaplasty/ 9715
2 ((breast adj2 reconstruct*) or mammaplast* or
(breast adj2 conserv* surg*)).ti,ab.
14,151
3 1 or 2 18,182
4 Transplantation, Autologous/ and Adipose Tissue/ 1034
5 Adipose Tissue/tr [Transplantation] 3023
6 Adipose Tissue/ and Tissue Transplantation/ 92
7 (autologous and ((fat* or adipos*) adj5 (graft* or
transplant* or transfer* or inject*))).ti,ab.
1732
8 ((fat* or adipos*) and (graft* or transplant* or
transfer* or inject*)).ti.
5978
9 ((autograft* or autotransplant*) adj3 (fat* or
adipos*)).ti,ab.
120
10 (lipostructur* or lipomodel* or lipofill* or
lipotransfer* or lipotransplant* or lipo-structur* or
lipo-model* or lipo-fill* or lipo-transfer* or lipo-
transplant*).ti,ab.
517
11 4 or 5 or 6 or 7 or 8 or 9 or 10 8444
12 3 and 11 548
13 limit 12 to yr=‘‘2014 -Current” 257
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The population of interest is all women undergoing immediate
or delayed breast reconstruction following either mastectomy,
quadrantectomy, wide-local-excision or lumpectomy in the treat-
ment of breast cancer will be included. Male and transgender cases
will be excluded.
7. Types of intervention
The interventions of interest include all AFG techniques used for
breast reconstruction following oncological surgery. AFG may
either be used for primary reconstruction (following mastectomy
or BCS) or secondary reconstruction (following an initial recon-
struction with implants or flaps). Studies reporting outcomes of
cadaveric fat grafts or pedicled fat flaps will be excluded. Studies
where AFG was used in conjunction with another reconstructive
technique (such as implants or flaps) will be excluded. Studies
where fat grafting is used for cosmetic breast augmentation, to
reconstruct traumatic breast detects (for example after amputa-
tion, ballistic or blast trauma or burns) will be excluded. Studies
where fat grafting is used as a salvage procedure for failed recon-
struction or purely for nipple reconstruction will be excluded.
8. Types of comparators
Where comparative studies are included, AFG may be compared
to implant-, flap-based reconstructions or no reconstruction at all.
9. Outcomes of interest
There will be six domains of outcomes of interest, defined as
follows:
(1) Oncological: defined as the incidence of new primary or
recurrent breast cancer.
(2) Clinical: defined as the incidence of intra- and post-
operative complications, including local infection, fat necro-
sis, oil cysts, palpable nodules. Complications will be graded
using the validated Clavien-Dindo classification system [22],
which asses the therapeutic consequences of complications.
(3) Aesthetic and functional: defined both: (1) subjectively as
the clinician satisfaction with the breasts, measured through
either questionnaire, visual analogue or the Netscher score
[23]; and (2) objectively through changes in the LENT-
SOMA score [24].
(4) Patient-reported: defined subjectively patient satisfaction
with the procedure, either measured by questionnaire,
visual analogue or other scales or formal instruments includ-
ing the BREAST-Q [25].
(5) Process: defined as the number of sessions required to
achieve satisfactory outcomes, expressed as a mean and
range for the group.
(6) Radiological: defined as the incidence of radiological abnor-
malities (calcification, microcalcification, cysts and other
masses) that may potentially interfere with mammographic
screening
10. Search methods for identification of studies
Electronic databases will be searched from 01 April 2014 to 21
August 2017. 01 April 2014 was chosen as a start date to update
literature since the search date of search of the previously pub-
lished systematic review/ meta-analysis [18]. The following fifteen
electronic databases will be searched: PubMed, MEDLINE,EMBASE, SCOPUS, CINAHL, PsychINFO, SciELO, The Cochrane
Library, including the Cochrane Central Register of Controlled Tri-
als (CENTRAL), Database of Abstracts of Reviews of Effect (DARE),
the Cochrane Methodology Register, Health Technology Assess-
ment Database, the NHS Economic Evaluation Databases and
Cochrane Groups, ClinicalTrials.gov, Current Controlled Trials Data-
base, the World Health Organisation (WHO) International Clinical
Trials Registry Platform, UpToDate.com, NHS Evidence and the
York Centre for Reviews and Dissemination.11. Search term and keywords
The search strategy has been designed with expert input, to
identify articles focused on ‘fat grafting and breast reconstruction’.
A search will be conducted suing appropriate keywords in English
combined with Boolean logical operators as follows: lipostructur-
ing OR lipotransfer OR lipomodelling OR lipomodeling [Title/
Abstract] OR ‘‘adipose tissue/transplantation” [MeSH Terms] OR
fat OR ‘‘autologous fat” OR ‘‘adipose tissue” OR ‘‘body fat” OR ‘‘tis-
sue adipose” OR ‘‘fatty tissue” [Title/Abstract] OR ‘‘adipose tissue”
[MeSH Terms] AND (autograft⁄ OR auto-transplant⁄ OR graft⁄ OR
transplant OR transplantat⁄ OR injection OR transfer OR lipofilling
[Title/Abstract]) AND (mammoplast⁄ OR mammaplast⁄ [Title/
Abstract]) OR ‘‘mammaplasty” [MeSH Terms]) OR (‘‘breast recon-
struction” OR ‘‘breast reconstructed” OR ‘‘breast augmentation”
OR ‘‘breast enlargement” OR ‘‘breast surgery” [Title/Abstract]),
adapted to the appropriate syntax of each database. An example
of the search strategy used on MEDLINE is shown in Table 1.
Articles will not be excluded based on publication status. The
search will not be limited to articles written in English. Articles
written in a non-English language can proceed to abstract screen-
ing (since the abstract will be in English), and if full-text is required
to determine eligibility the authors of the manuscript will firstly be
contacted to ask for an English translation, if this is not possible a
native speaker will be asked to translate, if this is not possible Goo-
gle translate (Google, Mountain View, California, USA), a recog-
nised as an approach to minimise language bias in systematic
reviews [26], will be used.12. Searching other resources
The grey literature will also be searched. Open Grey http://
www.opengrey.eu will be searched. The references of all included
R.A. Agha et al. / International Journal of Surgery Protocols 5 (2017) 22–26 25papers and prior systematic reviews will be searched for any rele-
vant studies that were not already captured through our search.
The Conference proceedings from the ACS and ASPS Annual Con-
gresses in 2012 and the European Plastic Surgery Research Council
(EPSRC) Annual Meetings of 2012 and 2013 will be searched to
capture recent as yet unpublished studies. Researchers actively
contributing to this field will be identified from published articles
‘author of correspondence’ and will contacted directly to ask about
further published or unpublished studies. The link to the PROS-
PERO record for the protocol will be advertised on the lead author’s
Twitter account to call for unpublished work made.
13. Identification and selection of studies
The articles identified from the electronic and manual searches
will be recorded into a Microsoft Excel 2017 database and dupli-
cates excluded (Microsoft, Redmond, Washington, USA), along
with the citation, titles and abstract.
Two trained teams, acting independently, will screen articles for
inclusion in two stages.
(1) Titles and abstract.
(2) Full text.
Any discrepancies at each stage will be resolved by consensus to
reach a final agreed list of articles. If consensus cannot be resolved
a senior author with arbitrate. The full text will also be reviewed
for any articles where doubt over inclusion exists after review of
the title and abstract. Multiple reports of the same study will be
linked together. If necessary authors may be contacted to clarify
study eligibility, results, or to access an article. Articles that meet
inclusion criteria will proceed to data extraction.
14. Data extraction, collection and management
Data extraction will be performed by two teams, acting inde-
pendently, with discrepancies resolved by consensus, or senior
author arbitration. Data will be input into a preformatted Microsoft
Excel 2017 database (Microsoft, Redmond, Washington, USA)
under standardised extraction fields to facilitate easy and consis-
tent data entry. The same extraction fields will be used to those
in the previous systematic review [18] to enable a comparison
and synthesis of results. The following data will be extracted:
(1) Article demographics: name, country and year of
publication.
(2) Study design and level of evidence according to Oxford Cen-
tre for Evidence-based medicine.
(3) Conflicts of interest and funding.
(4) Number of participants.
(5) Number of breasts treated.
(6) Age of participants, expressed as mean or median with
ranges, where reported.
(7) Previous oncological surgery: mastectomy, quadrantectomy,
lumpectomy or wide-local excision.
(8) Prior adjuvant radiotherapy.
(9) Previous breast reconstruction procedure(s).
(10) Time interval between oncological surgery.
(11) Donor site(s) used.
(12) Techniques: recipient site preparation, graft harvest, prepa-
ration and injection.
(13) Mean volume of fat injected per breast.
(14) Mean follow-up length.
(15) Loss to follow-up expressed as a percentage.(16) Oncological, clinical, aesthetic/functional, patient-reported,
process and radiological outcomes as defined above.
15. Data analysis
The outcomes of interest will be tabulated. Basic descriptive
statistics including weighted means, ranges and standard devia-
tions of the mean will be used to provide appropriate summary
of the data. Review Manager V.5.2.6 (RevMan) [27] will be used
to assess the heterogeneity of comparative studies (Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration. Review
Manager (RevMan) Version 5.2. 2012). If the heterogeneity is sub-
stantial, defined by the Inconsistency Index (I2) of >75% [28], a
meta-analysis will not be conducted. Results will be both com-
pared and synthesised in additional analyses with those from the
previous systematic review conducted by our group [18].
16. Subgroup analysis
Additional analyses will be conducted to separate AFG used for
total breast reconstructions post-mastectomy and AFG used to cor-
rect contour deformities post-implant, flap- based reconstructions
or BCS alone.
17. Assessment of bias
The Grading of Recommendation Assessment, Development and
Evaluation (GRADE) system [19,27] will be used to assess the
methodological quality of included studies. The GRADE system
offers four levels of evidence: high; moderate; low; very low. RCTs
are considered highest level of evidence. Case series and case
reports are ‘very low’. Quality may be downgraded along five
domains: (1) Study design or implementation limitations; (2)
Inconsistency in results; (3) Indirectness of evidence; (4) Impreci-
sion of estimates; and (5) Publication bias. Quality may be
upgraded because of three domains: (1) A very large magnitude
of effect; (2) A dose–response gradient; (3) All plausible biases
would reduce an apparent treatment effect. For RCTs it will be doc-
uments: (1) whether or not clinically relevant outcomes are
reported; (2) whether results are comparable with protocols and
subsequent publications where available. Key missing information
across all study types such as complication rates and follow-up
times will be documented and assessed.
18. Dissemination
This systematic review will provide a comprehensive up-to-
date evaluation of the use of AFG for breast reconstruction. Results
have the potential to influence the management of patients with
breast cancer postmastectomy or BCS and the reconstructive
options offered to them. Results from this systematic review,
alongside the previously reported findings in the literature, will
lead to conclusions and recommendations for clinicians, research-
ers, plastic surgical societies and policy makers. The manuscript
will be published in English in a peer-reviewed journal. The
authors will respond to any commentary generated. The findings
will be presented at national and international meetings within
the fields of plastic, reconstructive and aesthetic surgery, general
surgery and surgical oncology. The work will be disseminated elec-
tronically and in print to leading researchers in the field. Brief
reports of the review findings will be disseminated directly to
the appropriate audiences and societies through email and other
modes of communication. Updates of the review could be con-
ducted to inform and guide healthcare practice and policy should
26 R.A. Agha et al. / International Journal of Surgery Protocols 5 (2017) 22–26the need arise. Authors of position statements and guidelines relat-
ing to AFG will be informed of the results directly.
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